|
Discover how the IsoPSA Test supported shared decision-making in a BPH patient with elevated PSA.
|
|
Addressing PSA Skepticism in Clinical Practice with the IsoPSA Test
|
|
Like many urologists, Dr. Aaron Berger, Chief Medical Officer for Associated Urological Specialists, encounters patients who are hesitant to pursue further testing or biopsy following an elevated PSA result.
|
|
In this case study, Dr. Berger used the IsoPSA Test to better assess the patient’s risk and support shared decision-making.
|
|
|
|
|
The patient was a 58-year-old man being treated for benign prostatic hyperplasia (BPH) with a PSA of 6.1 ng/mL. Adding complexity to the case, the patient was unable to undergo multiparametric MRI (mpMRI) due to claustrophobia. By incorporating the IsoPSA Test into the evaluation, Dr. Berger was able to help address the patient’s concerns and move forward with appropriate next steps.
|
|
Watch this short case to see how the IsoPSA Test can help clinicians navigate PSA skepticism and make confident decisions together with their patients.
|
|
|
Receive education updates and resources
|
|
Subscribe to learn more about the IsoPSA Test and receive updates when new CME programs, webinars, and case studies are available.
|
|
|
This material concerns the IsoPSA Test, a laboratory developed test (LDT) from Cleveland Diagnostics, Inc., which is performed by CLIA-certified laboratories qualified to conduct high-complexity clinical testing and is only intended for use consistent with applicable CLIA requirements. When offered as an LDT, the IsoPSA Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
|
|
|
|
